Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Andrx Labs and Watson Laboratories, subsidiaries of Watson Pharmaceuticals, have submitted abbreviated new drug applications (ANDAs) for marketing Oxycodone Hydrochloride extended-release tablets in the 10, 15, 20, 30, 40, 60 and 80mg strengths with the US Food and Drug Administration.
Subscribe to our email newsletter
Watson claims that its Oxycodone Hydrochloride extended-release tablets are the generic version of Purdue Pharma’s treatment, OxyContin for the management of moderate to severe when continuous, around-the-clock opioid analgesic is needed for an extended period of time.
Purdue Pharma filed a lawsuit against Watson in the in the US District Courts for the Southern District of New York, District of Delaware and Southern District of Florida, to restrict the company for commercializing the drug prior to the expiration of the US patents numbers 6,488,963, 7,674,799, 7,674,800, 7,683,072 and 7,776,314.